• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

AxoGen

Abbott structural heart exec takes corner office at Axogen

August 8, 2024 By Sean Whooley

Axogen (Nasdaq:AXGN) announced today that it appointed Michael Dale, former SVP of Abbott’s Structural Heart unit, as its new CEO and board member. Dale’s appointment goes into effect tomorrow, Aug. 9, 2024. He succeeds Karen Zaderej, who intends to remain in an advisory role for nine months. Axogen also announced that it named Paul Thomas […]

Filed Under: Business/Financial News, Featured, Implants, Neurological Tagged With: AxoGen, Personnel Moves

Axogen launches Avive+ Soft Tissue Matrix

June 24, 2024 By Danielle Kirsh

Axogen (Nasdaq:AXGN) today announced it has launched its Avive+ Soft Tissue Matrix. Avive+ is intended to be used as a soft tissue barrier. It is a resorbable and multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during peripheral nerve healing. “Product innovation is integral to our mission at Axogen,” CEO and President […]

Filed Under: Implants, Pain Management Tagged With: AxoGen

Axogen announces first surgical implant of Avive+ Soft Tissue Matrix

April 30, 2024 By Danielle Kirsh

Axogen (Nasdaq:AXGN) this week announced the first surgical implantation of its Avive+ Soft Tissue Matrix. Avive+ is a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of nerve healing. The soft tissue matrix is processed and distributed as a 361 tissue product in accordance with FDA Good Tissue Practices […]

Filed Under: Wound Care Tagged With: AxoGen

Axogen has positive nerve implant data

January 19, 2024 By Sean Whooley

Axogen (Nasdaq:AXGN) announced positive topline results from a clinical study evaluating its Axoguard Nerve Cap. The REPOSE study compares standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with the Axoguard Nerve Cap. Axoguard Nerve Cap is a proprietary surgical implant. Derived from porcine submucosal extracellular matrix remodeled during healing, […]

Filed Under: Clinical Trials, Implants, Neurological Tagged With: AxoGen

Axogen launches AxoGuard HA+ nerve protector

September 5, 2023 By Sean Whooley

Axogen (Nasdaq:AXGN) announced today that it fully launched its Axoguard HA+ nerve protector for peripheral nerve injury protection. The company designed the proprietary device to provide both short- and long-term protection for those nerve injuries. It features a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel facilitates enhanced nerve […]

Filed Under: Business/Financial News, Neurological Tagged With: AxoGen

Axogen appoints Jens Schroeder Kemp as chief marketing officer

February 13, 2023 By Danielle Kirsh

Axogen today announced it appointed Jens Schroeder Kemp as chief marketing officer. Kemp has more than 20 years of strategic marketing, sales and business development experience in the medical device industry. He will report directly to CEO and President Karen Zaderej. “I am thrilled to welcome Jens to Axogen. His extensive strategic marketing experience and […]

Filed Under: Business/Financial News, Neuromodulation/Neurostimulation, Pain Management Tagged With: AxoGen, Personnel Moves

AxoGen beats The Street in Q3 results

November 7, 2019 By Danielle Kirsh

AxoGen (NSDQ:AXGN) posted third-quarter results today that beat the consensus forecast on Wall Street. The Alachua, Fla.-based company reported losses of -$6.1 million, or -14¢, on sales of $28.6 million for the three months ended Sept. 30, 2019, for a bottom-line gain of 26.4% sales growth of 26% compared with Q3 2018. Adjusted to exclude one-time […]

Filed Under: Featured, Wall Street Beat Tagged With: AxoGen

Axogen shares slip on expanded Avance nerve graft study

April 22, 2019 By Brad Perriello

AxoGen (NSDQ:AXGN) today expanded a study of its Avance graft for treating peripheral nerve damage on a pre-specified statistical analysis, sending its share price down slightly today. Alachua, Fla.-based AxoGen is adding 50 patients and five new centers to the Recon study of Avance, a human allograft designed to bridge severed nerves without a second surgical […]

Filed Under: Clinical Trials, Featured, Wall Street Beat Tagged With: AxoGen, Peripheral

ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019

January 29, 2019 By Fink Densford

ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]

Filed Under: Business/Financial News, Featured Tagged With: Adherium Limited, AliveCor, AxoGen, Biocoat, Cardinal Health, Cirtec Medical, Functional Neuromodulation, georgiabio, iCad Inc., Ra Medical, ReShape Lifesciences, SPR Therapeutics, vasculardynamics

Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves – January 8, 2019

January 8, 2019 By Fink Densford

Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The Acton, Mass.-based diabetes-focused medtech company said that McMillan will join the company in February and that Levitz will continue as an advisor for a period following the […]

Filed Under: Business/Financial News, Featured Tagged With: AxoGen, Bonesupport, Cerus Corp., GI Dynamics, Insulet, Livongo, Medidata Solutions, Medtronic, pressaomedical, quantadialysistech, Reva Medical Inc., Senseonics, Smith & Nephew, taelifesciences, wrightmedical

AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat

January 7, 2019 By Brad Perriello

AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: AtriCure Inc., AxoGen, Cerus Corp., OrthoPediatrics Corp., Sientra, STAAR Surgical Co

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy